Key Highlights

  • Akari Therapeutics signed a preclinical research collaboration with Whitehawk Therapeutics to test its PH1 payload alongside Whitehawk's topoisomerase I platform, the first outside validation of Akari's dual-payload ADC approach.
  • Second-quarter results revealed $12.1 million in non-cash impairments against Goodwill and its lead candidate AKTX-101, pushing the six-month net loss to $19.3 million despite far smaller cash operating costs.
  • The company holds just $7.7 million in cash and explicitly states this is insufficient to fund operations for the next twelve months, with a Phase 1 trial for AKTX-101 still targeted for mid-2027.

Akari Therapeutics Plc (NASDAQ:AKTX) has spent 2026 rebuilding itself around one idea: a cancer-drug payload that attacks tumours by jamming the machinery cells use to edit their own genetic instructions.

On 13 August the UK-incorporated, Tampa-headquartered company reported second-quarter results that put the promise and the pressure of that strategy on the same page. In July it signed a research collaboration with Whitehawk Therapeutics, the first time an outside developer has agreed to test Akari's chemistry alongside its own.

The same period carried $12.1 million of non-cash impairments and a going-concern warning. The question is whether partnership-led validation can outrun a Balance Sheet the company says cannot fund twelve more months.

What Happened

On 21 July 2026 Akari announced a strategic research collaboration with Whitehawk Therapeutics. The work is preclinical and centres on dual-payload antibody-drug conjugates, or ADCs: a targeting antibody chemically linked to a toxic drug, so the toxin reaches mainly tumour cells rather than healthy tissue.

Almost every approved ADC carries one class of payload. The collaboration pairs Akari's PH1 spliceosome-modulating payload with Whitehawk's topoisomerase I inhibitor platform to test whether two killing mechanisms on one construct broaden activity. Akari leads the studies; financial terms were not disclosed, and interim updates are expected as work progresses.

Chief executive Abizer Gaslightwala called it a first step in exploring how PH1 combines with current ADC payload classes; Whitehawk chief executive Dave Lennon said dual-payload approaches could expand his platform. Akari's 13 August results reiterated that lead candidate AKTX-101 remains on track for a first-in-human Phase 1 trial in mid-2027.

Why It Matters

PH1 is an analog of a bacterial toxin that disrupts RNA splicing, the step in which a cell converts raw pre-mRNA into the mature template used to build proteins. Akari says it kills tumour cells directly and can also generate neoantigens, abnormal protein fragments that flag the tumour to the immune system.

That differs from the topoisomerase I inhibitors dominating approved ADCs, and the difference is what the Whitehawk work probes. A payload platform can be licensed repeatedly across multiple antibodies and partners, for Akari the only realistic route to non-dilutive income.

Supporting evidence arrived at ASCO 2026, where an online abstract reported that AKTX-101 produced synergistic cell killing when combined with adagrasib, an approved KRAS inhibitor, in pancreatic cancer cell lines carrying KRAS G12D and G12C mutations. Comparator TROP2 ADCs using topoisomerase I payloads showed antagonism in the same setting.

The Numbers

Akari held $7.7 million in cash at 30 June 2026, up from $5.2 million at 31 December 2025. R&D spending rose to $2.1 million in the quarter from $0.7 million a year earlier, while G&A was unchanged at $2.5 million. Quarterly net loss widened to $4.8 million from $1.9 million.

The half-year picture is heavier. First-half R&D was $3.5 million and G&A $4.7 million, yet the six-month net loss reached $19.3 million because of $12.1 million of non-cash impairments: $8.4 million against goodwill and $3.7 million against the in-process research value assigned to AKTX-101. A May late-filing notice had flagged that a sustained decline in Market Capitalisation relative to net asset carrying value would trigger the charge.

Accumulated Deficit stood at $283.8 million and shareholders' Equity at $18.6 million. The cash increase came from about $8.6 million of gross financing proceeds, roughly $8.0 million net: a $5.5 million private Placement at $3.74 per American Depositary Share plus about $3.1 million from Warrant exercises.

What It Means for the Company

Akari is now an ADC payload company in all but name. Nomacopan, the complement inhibitor that defined the Business for years, is described in the FY2025 Annual Report as a programme for which management is seeking external partners for out-licensing, and it does not appear in the latest quarterly report.

The strategy is concentrated: prove PH1 through partnerships and preclinical data while pushing AKTX-101, a TROP2-targeting ADC, toward the clinic. TROP2 is already a validated ADC target, placing the burden of differentiation on the payload.

The company secured a European Patent in May and an Australian patent in April covering PH1, and in July appointed Patricia LoRusso, D.O., a former president of the American Association for Cancer Research, to its scientific advisory board. One structural issue is also resolved: after changing its ADS ratio effective 31 March 2026 so that one ADS represents 80,000 ordinary shares, up from 2,000, Nasdaq notified Akari that it had regained compliance with the minimum bid price requirement.

Risks Investors Should Watch

The most serious disclosure is the going-concern statement. Akari says its $7.7 million cash balance is not sufficient to fund operations for one year following issuance of the financial statements, raising substantial doubt about its ability to continue as a going concern.

Dilution is the near-certain consequence. Series H, I and J warrants from the June placement each cover 1,470,588 ADSs at $3.74, roughly 4.4 million in total, and the ordinary share count now runs to about 155.8 billion shares.

The impairments are non-cash but not cosmetic: writing down goodwill and the carrying value of AKTX-101 reflects a valuation below book value.

Scientifically, everything remains preclinical. The KRAS synergy data come from cell lines, not patients, and the Whitehawk collaboration has no disclosed Economics or milestones. A mid-2027 Phase 1 start depends on IND-enabling work completing and being funded.

What Comes Next

The nearest checkpoints are interim readouts from the Whitehawk studies. Any sign that PH1 and a topoisomerase I payload work together without interference would be the first external validation of the platform.

Beyond that, the milestone that matters is completing IND-enabling studies for AKTX-101 and opening the Phase 1 trial targeted for mid-2027. Investors should also watch for further out-licensing or collaboration announcements.

The third-quarter report due in November will show how quickly the $7.7 million is consumed and whether Akari has raised again. Out-licensing nomacopan would be a separate, so far unquantified, source of value.

Conclusion

Akari is racing to prove its payload platform has value beyond its own balance sheet, and the Whitehawk collaboration is the first sign an outside developer agrees. But the same quarter that brought that validation also brought a $12.1 million writedown and a plain going-concern statement, and neither preclinical data nor a Partnership with undisclosed economics changes the fact that $7.7 million doesn't fund a full year. The interim Whitehawk readouts and any further out-licensing news, not the mid-2027 Phase 1 timeline, are what will show whether this platform strategy can outrun its own cash burn.